Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel Design, Single Dose, 2-arm Study Comparing the Pharmacokinetic, Safety and Immunogenicity Profiles of AVT03 and US-Xgeva® in Healthy Male Subjects

NCT05876949 is registered in ClinicalTrials.gov with Alvotech Swiss AG as lead sponsor.

NCT NCT05876949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05876949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel Design, Single Dose, 2-arm Study Comparing the Pharmacokinetic, Safety and Immunogenicity Profiles of AVT03 and US-Xgeva® in Healthy Male Subjects
Lead sponsor
Alvotech Swiss AG
Phase
Phase 1
Overall status
Completed
Start date
July 21, 2023
Completion date
April 15, 2024
Enrollment
208 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

this is a phase i study conducted in healthy volunteers